GEN-011

GEN-011 is an investigational, personalized adoptive cell therapy developed for the treatment of advanced solid tumors. It consists of autologous (patient-derived) CD4+ and CD8+ T cells that are specific for neoantigens identified from each patient’s tumor using Genocea’s proprietary ATLAS platform. These neoantigen-specific T cells are expanded ex vivo using the PLANET process and then infused back into the patient to target and kill tumor cells expressing those neoantigens. The therapy is administered intravenously, with or without prior lymphodepletion, and is followed by interleukin-2 (IL-2) as costimulatory support. GEN-011 was being evaluated in a Phase 1/2a clinical trial (TiTAN) in patients with various refractory solid tumors including melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, urothelial carcinoma, renal cell carcinoma, small cell lung cancer, cutaneous squamous cell carcinoma, and anal squamous cell carcinoma. Development was discontinued due to business reasons.

Other names

autologous neoantigen-specific T lymphocytes GEN-011